Literature DB >> 8453509

A combination of calcitonin and bisphosphonate for the emergency treatment of severe tumor-induced hypercalcemia.

K Luce, D E O'Donnell, A R Morton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8453509     DOI： 10.1007/bf00675630

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  5 in total

1.  Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.

Authors:  D Thiébaud; P Jaeger; A F Jacquet; P Burckhardt
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

2.  Dose of bisphosphonate for hypercalcaemia of malignancy.

Authors:  A R Morton; J Friefeld; F Halperin
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

3.  Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.

Authors:  R Gucalp; P Ritch; P H Wiernik; P R Sarma; A Keller; S P Richman; K Tauer; J Neidhart; L E Mallette; R Siegel
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

4.  Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.

Authors:  S H Ralston; S J Gallacher; U Patel; F J Dryburgh; W D Fraser; R A Cowan; I T Boyle
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

5.  Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.

Authors:  A R Morton; J A Cantrill; A E Craig; A Howell; M Davies; D C Anderson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.